Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZVRA vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZVRA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

ZVRA Overall Winner 6-Pillar Tally: ZVRA 5 – 1 DMAC Matrix Metrics: ZVRA 9 – 1 DMAC

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.31 (9.3x Forward P/E, 31.5% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZVRA vs DMAC
ZVRA NASDAQ Head-to-Head Winner
Zevra Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.31
+2.53% 1D
Market Cap $664.1M
TTM Revenue $148M
Forward P/E 9.3x
Beta / 30D Vol 1.18β · 95% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 39
RSI-14: 38.9 · SMA20: $10.53 · SMA50: $10.92
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (ZVRA 5 – 1 DMAC)

Columns: Metric · ZVRA · DMAC
1. Valuation Multiples ZVRA
Forward P/E 9.3x N/M
Trailing P/E 9.7x N/M
PEG Ratio 10.67x N/M
EV / Revenue 3.7x N/M
2. Growth & Scale ZVRA
Revenue Growth (YoY) +44.9% +0.0%
Earnings Growth (YoY) -88.4% +0.0%
TTM Revenue (USD) $148M N/A
Market Cap $664.1M $503.1M
3. Profitability & Quality ZVRA
Gross Margin 95.4% N/A
Operating Margin 31.5% 0.0%
Net Profit Margin 52.8% 0.0%
Return on Equity (ROE) 41.9% -114.6%
4. Balance Sheet & Cash Flow ZVRA
Cash Generation (TTM) $38M -$32M
Cash Flow Margin 25.9% N/A
Net Cash / Leverage $121M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 71.7% (14th %ile) 106.3% (14th %ile)
Put/Call OI Skew 1.62x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ZVRA
OpEx & R&D Intensity 63.9% of Rev ($94M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZVRA (9) vs DMAC (1)
Institutional Metric ZVRA DMAC Criterion Row Edge
Market Capitalization
Scale
$664.1M $503.1M Larger Scale ZVRA
Trailing P/E Ratio
Valuation
9.7x N/M Lower Multiple ZVRA
Forward P/E Ratio
Valuation
9.3x N/M Lower Multiple ZVRA
Revenue Growth (YoY)
Growth
+44.9% +0.0% Higher Growth ZVRA
Operating Margin (TTM)
Profitability
31.5% 0.0% Higher Margin ZVRA
Net Profit Margin
Profitability
52.8% 0.0% Higher Margin ZVRA
Return on Equity (ROE)
Capital Efficiency
41.9% -114.6% Higher ROE ZVRA
52-Week Range Position
Momentum
18% ($8–$15) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.18β · 95% Vol 1.74β · 98% Vol Lower Realized Risk ZVRA
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite ZVRA
Trailing 12M Revenue (USD)
Operating Scale
$148M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
95.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.67x PEG · 3.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$38M ($121M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +17.5 pp
ZVRA: -6.34% · DMAC: +11.16%
3M Horizon DMAC +46.84 pp
ZVRA: -19.53% · DMAC: +27.31%
6M Horizon DMAC +58.89 pp
ZVRA: -10.74% · DMAC: +48.15%
1Y Horizon DMAC +54.39 pp
ZVRA: +0.87% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ZVRA Revenue DMAC Revenue ZVRA Op. Margin DMAC Op. Margin Margin Leader
FY2018 N/A $0M N/A -1352.2% DMAC
FY2019 $10M N/A -158.4% N/A ZVRA
FY2020 $10M N/A -42.2% N/A ZVRA
FY2021 $30M N/A 27.0% N/A ZVRA
FY2022 $10M N/A -418.9% N/A ZVRA
FY2023 $30M N/A -180.6% N/A ZVRA
FY2024 $20M N/A -368.5% N/A ZVRA
FY2025 $110M N/A -59.1% N/A ZVRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZVRA BREAKDOWN
111d in phase · OBV DISTRIBUTION
Current IV 71.7%
IV Percentile 14th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ZVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZVRA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $664.1M market capitalization and 31.5% operating margin.
OpEx & R&D Reinvestment 63.9% of Rev ($94M)
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZVRA vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.31 (9.3x Forward P/E, 31.5% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZVRA leads the Growth & Scale pillar: ZVRA posts +44.9% YoY revenue growth and -88.4% YoY earnings growth on $148M TTM revenue (95.4% gross margin, 31.5% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ZVRA cumulative revenue shifted +1000.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, ZVRA deploys 63.9% of Rev ($94M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

ZVRA screens cheaper on headline valuation multiples. ZVRA trades at 9.3x Forward P/E, 9.7x Trailing P/E, 10.67x PEG, and 3.7x EV/Revenue (25.9% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZVRA (41.9% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ZVRA carries 71.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 95% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.